Загрузка...
Optimising infliximab induction dosing for patients with ulcerative colitis
AIMS: The therapeutic failure of infliximab therapy in patients with ulcerative colitis remains a challenge even 2 decades after its approval. Therapeutic drug monitoring (TDM) has shown value during maintenance therapy, but induction therapy has still not been explored. Patients may be primary nonr...
Сохранить в:
| Опубликовано в: : | Br J Clin Pharmacol |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6422726/ https://ncbi.nlm.nih.gov/pubmed/30634202 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13859 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|